GlassScriptPhysician profile
Nisha Kotecha
NPI 1073873956
$1,950.13
in general payments reported to CMS, 2019-2025
19 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $44.72 · 2021: $152 · 2022: $253 · 2023: $445 · 2024: $358 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.79 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $585.01 | 2021-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $392.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.31 | 2019-2025 | Stiolto Respimat, Jascayd, Ofev |
| Regeneron Healthcare Solutions, INC. | $143.74 | 2022-2025 | Dupixent |
| Amgen INC. | $143.05 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $90.64 | 2020-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $66.86 | 2019-2023 | |
| Incyte Corporation | $50.67 | 2021-2022 | |
| Genentech USA, INC. | $49.16 | 2023 | Xolair |
| Genzyme Corporation | $45.13 | 2021-2024 | |
| Viatris Specialty LLC | $33.62 | 2025 | Yupelri |
| Kaleo, INC. | $32.35 | 2022-2023 | Auvi-Q |
| Insmed, INC. | $31.95 | 2021-2025 | Arikayce |
| Octapharma USA, INC. | $31.14 | 2021-2022 | |
| Axsome Therapeutics, INC. | $20.93 | 2024 | Sunosi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $18.21 | 2023 | |
| United Therapeutics Corporation | $15.03 | 2025 | Tyvaso |
| Jazz Pharmaceuticals INC. | $14.15 | 2020 | |
| Aimmune Therapeutics, INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Kotecha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.